Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells

Authors: Samia B Bachmann, Sandra C Frommel, Rosalba Camicia, Hans C Winkler, Raffaella Santoro, Paul O Hassa

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Prostate cancer (PCa) is one of the leading causes of cancer-related mortality and morbidity in the aging male population and represents the most frequently diagnosed malignancy in men around the world. The Deltex (DTX)-3-like E3 ubiquitin ligase (DTX3L), also known as B-lymphoma and BAL-associated protein (BBAP), was originally identified as a binding partner of the diphtheria-toxin-like macrodomain containing ADP-ribosyltransferase-9 (ARTD9), also known as BAL1 and PARP9. We have previously demonstrated that ARTD9 acts as a novel oncogenic survival factor in high-risk, chemo-resistant, diffuse large B cell lymphoma (DLBCL). The mono-ADP-ribosyltransferase ARTD8, also known as PARP14 functions as a STAT6-specific co-regulator of IL4-mediated proliferation and survival in B cells.

Methods

Co-expression of DTX3L, ARTD8, ARTD9 and STAT1 was analyzed in the metastatic PCa (mPCa) cell lines PC3, DU145, LNCaP and in the normal prostate luminal epithelial cell lines HPE and RWPE1. Effects on cell proliferation, survival and cell migration were determined in PC3, DU145 and/or LNCaP cells depleted of DTX3L, ARTD8, ARTD9, STAT1 and/or IRF1 compared to their proficient control cells, respectively. In further experiments, real-time RT-PCR, Western blot, immunofluorescence and co-immunoprecipitations were conducted to evaluate the physical and functional interactions between DTX3L, ARTD8 and ARTD9.

Results

Here we could identify DTX3L, ARTD9 and ARTD8 as novel oncogenic survival factors in mPCa cells. Our studies revealed that DTX3L forms a complex with ARTD8 and mediates together with ARTD8 and ARTD9 proliferation, chemo-resistance and survival of mPCa cells. In addition, DTX3L, ARTD8 and ARTD9 form complexes with each other. Our study provides first evidence that the enzymatic activity of ARTD8 is required for survival of mPCa cells. DTX3L and ARTD9 act together as repressors of the tumor suppressor IRF1 in mPCa cells. Furthermore, the present study shows that DTX3L together with STAT1 and STAT3 is implicated in cell migration of mPCa cells.

Conclusions

Our data strongly indicate that a crosstalk between STAT1, DTX3L and ARTD-like mono-ADP-ribosyltransferases mediates proliferation and survival of mPCa cells. The present study further suggests that the combined targeted inhibition of STAT1, ARTD8, ARTD9 and/or DTX3L could increase the efficacy of chemotherapy or radiation treatment in prostate and other high-risk tumor types with an increased STAT1 signaling.
Appendix
Available only for authorised users
Literature
1.
2.
Wegiel B, Evans S, Hellsten R, Otterbein LE, Bjartell A, Persson JL: Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Cancer Drug Targets. 2010, 10 (4): 392-401.CrossRefPubMed
3.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY: The genomic complexity of primary human prostate cancer. Nature. 2011, 470 (7333): 214-220.PubMedCentralCrossRefPubMed
4.
Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM: Staging of prostate cancer. Histopathology. 2012, 60 (1): 87-117.CrossRefPubMed
5.
Rubin MA, Maher CA, Chinnaiyan AM: Common gene rearrangements in prostate cancer. J Clin Oncol. 2011, 29 (27): 3659-3668.CrossRefPubMed
6.
Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT: Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem. 2003, 278 (29): 27287-27292.CrossRefPubMed
7.
Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT: Stat3 promotes metastatic progression of prostate cancer. Am J Pathol. 2008, 172 (6): 1717-1728.PubMedCentralCrossRefPubMed
8.
9.
Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, Enkemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006, 12 (1): 11-19.CrossRefPubMed
10.
Yu H, Jove R: The STATs of cancer–new molecular targets come of age. Nat Rev Cancer. 2004, 4 (2): 97-105.CrossRefPubMed
11.
Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, Mauceri HJ, Roizman B, Weichselbaum RR: Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 2007, 67 (19): 9214-9220.CrossRefPubMed
12.
Khodarev NN, Roizman B, Weichselbaum RR: Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res. 2012, 18 (11): 3015-3021.CrossRefPubMed
13.
Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman CN, Mitchell JB, Chuang EY: Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. Cancer Res. 2007, 67 (8): 3845-3852.CrossRefPubMed
14.
Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ: An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A. 2008, 105 (47): 18490-18495.PubMedCentralCrossRefPubMed
15.
Patterson SG, Wei S, Chen X, Sallman DA, Gilvary DL, Zhong B, Pow-Sang J, Yeatman T, Djeu JY: Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene. 2006, 25 (45): 6113-6122.CrossRefPubMed
16.
Pitroda SP, Wakim BT, Sood RF, Beveridge MG, Beckett MA, MacDermed DM, Weichselbaum RR, Khodarev NN: STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009, 7: 68-PubMedCentralCrossRefPubMed
17.
Cochet O, Frelin C, Peyron JF, Imbert V: Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006, 18 (4): 449-455.CrossRefPubMed
18.
El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ: Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res. 2004, 64 (10): 3436-3443.CrossRefPubMed
19.
Legrand A, Vadrot N, Lardeux B, Bringuier AF, Guillot R, Feldmann G: Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation. Liver Int. 2004, 24 (2): 149-160.CrossRefPubMed
20.
Greenwood C, Metodieva G, Al-Janabi K, Lausen B, Alldridge L, Leng L, Bucala R, Fernandez N, Metodiev MV: Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer. J Proteomics. 2012, 75 (10): 3031-3040.CrossRefPubMed
21.
Sun Y, Cheng MK, Griffiths TR, Mellon JK, Kai B, Kriajevska M, Manson MM: Inhibition of STAT signalling in bladder cancer by diindolylmethane: relevance to cell adhesion, migration and proliferation. Curr Cancer Drug Targets. 2013, 13 (1): 57-68.CrossRefPubMed
22.
Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, Nomikos A, Papadimitriou C, Nakopoulou L: Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology. 2012, 60 (7): 1125-1132.CrossRefPubMed
23.
Camicia R, Bachmann SB, Winkler HC, Beer M, Tinguely M, Haralambieva E, Hassa PO: BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNgamma-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma. J Cell Sci. 2013, 126 (Pt 9): 1969-1980.CrossRefPubMed
24.
25.
Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A: STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004, 279 (7): 5811-5820.CrossRefPubMed
26.
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001, 19: 623-655.CrossRefPubMed
27.
Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E: IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res. 2002, 22 (1): 39-47.CrossRefPubMed
28.
Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006, 6 (11): 836-848.CrossRefPubMed
29.
Meyer T, Hendry L, Begitt A, John S, Vinkemeier U: A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors. J Biol Chem. 2004, 279 (18): 18998-19007.CrossRefPubMed
30.
Meyer T, Vinkemeier U: Nucleocytoplasmic shuttling of STAT transcription factors. Eur J Biochem. 2004, 271 (23–24): 4606-4612.CrossRefPubMed
31.
Lodige I, Marg A, Wiesner B, Malecova B, Oelgeschlager T, Vinkemeier U: Nuclear export determines the cytokine sensitivity of STAT transcription factors. J Biol Chem. 2005, 280 (52): 43087-43099.CrossRefPubMed
32.
Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR: STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One. 2009, 4 (6): e5821-PubMedCentralCrossRefPubMed
33.
Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH: MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005, 116 (5): 824-829.CrossRefPubMed
34.
van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH: Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur J Cancer. 1999, 35 (4): 664-671.CrossRefPubMed
35.
Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST, Parkin JD: MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 2000, 3 (2): 66-75.CrossRefPubMed
36.
Zhong B, Sallman DA, Gilvary DL, Pernazza D, Sahakian E, Fritz D, Cheng JQ, Trougakos I, Wei S, Djeu JY: Induction of clusterin by AKT–role in cytoprotection against docetaxel in prostate tumor cells. Mol Cancer Ther. 2010, 9 (6): 1831-1841.CrossRefPubMed
37.
Hatano K, Yamaguchi S, Nimura K, Murakami K, Nagahara A, Fujita K, Uemura M, Nakai Y, Tsuchiya M, Nakayama M, Nonomura N, Kaneda Y: Residual Prostate Cancer Cells after Docetaxel Therapy Increase the Tumorigenic Potential via Constitutive Signaling of CXCR4, ERK1/2 and c-Myc. Mol Cancer Res. 2013, 11 (9): 1088-1100.CrossRefPubMed
38.
Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F: Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010, 35 (4): 208-219.CrossRefPubMed
39.
Cho SH, Goenka S, Henttinen T, Gudapati P, Reinikainen A, Eischen CM, Lahesmaa R, Boothby M: PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood. 2009, 113 (11): 2416-2425.PubMedCentralCrossRefPubMed
40.
Goenka S, Boothby M: Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. Proc Natl Acad Sci U S A. 2006, 103 (11): 4210-4215.PubMedCentralCrossRefPubMed
41.
Goenka S, Cho SH, Boothby M: Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription. J Biol Chem. 2007, 282 (26): 18732-18739.CrossRefPubMed
42.
Timinszky G, Till S, Hassa PO, Hothorn M, Kustatscher G, Nijmeijer B, Colombelli J, Altmeyer M, Stelzer EH, Scheffzek K, Hottiger MO, Ladurner AG: A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat Struct Mol Biol. 2009, 16 (9): 923-929.CrossRefPubMed
43.
44.
Forst AH, Karlberg T, Herzog N, Thorsell AG, Gross A, Feijs KL, Verheugd P, Kursula P, Nijmeijer B, Kremmer E, Kleine H, Ladurner AG, Schuler H, Luscher B: Recognition of mono-ADP-ribosylated ARTD10 substrates by ARTD8 macrodomains. Structure. 2013, 21 (3): 462-475.CrossRefPubMed
45.
Cho SH, Ahn AK, Bhargava P, Lee CH, Eischen CM, McGuinness O, Boothby M: Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family. Proc Natl Acad Sci U S A. 2011, 108 (38): 15972-15977.PubMedCentralCrossRefPubMed
46.
Barbarulo A, Iansante V, Chaidos A, Naresh K, Rahemtulla A, Franzoso G, Karadimitris A, Haskard DO, Papa S, Bubici C: Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene. 2012, 32 (36): 4231-4242.CrossRefPubMed
47.
Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC, Shipp MA: The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem. 2003, 278 (24): 21930-21937.CrossRefPubMed
48.
Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA: BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol. 2006, 26 (14): 5348-5359.PubMedCentralCrossRefPubMed
49.
Obiero J, Walker JR, Dhe-Paganon S: Fold of the conserved DTC domain in Deltex proteins. Proteins. 2012, 80 (5): 1495-1499.CrossRefPubMed
50.
Grunewald TG, Diebold I, Esposito I, Plehm S, Hauer K, Thiel U, da Silva-Buttkus P, Neff F, Unland R, Muller-Tidow C, Zobywalski C, Lohrig K, Lewandrowski U, Sickmann A: Prazeres da Costa O, Gorlach A, Cossarizza A, Butt E, Richter GH, Burdach S: STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res. 2012, 10 (1): 52-65.CrossRefPubMed
51.
Wilting SM, de Wilde J, Meijer CJ, Berkhof J, Yi Y, van Wieringen WN, Braakhuis BJ, Meijer GA, Ylstra B, Snijders PJ, Steenbergen RD: Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer. 2008, 47 (10): 890-905.PubMedCentralCrossRefPubMed
52.
Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Choudhary A, Darden W, Adai A, Latham G, Bishop J, Sharma R, Westra WH, Hennessey P, Chung CH, Califano JA: Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014, 74 (4): 1091-1104.PubMedCentralCrossRefPubMed
53.
Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA: BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Mol Cell. 2009, 36 (1): 110-120.PubMedCentralCrossRefPubMed
54.
Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene. 2001, 20 (10): 1152-1163.CrossRefPubMed
55.
Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 1994, 57 (3): 406-412.CrossRefPubMed
56.
Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line–a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980, 37: 115-132.PubMed
57.
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43 (4): 1809-1818.PubMed
58.
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979, 17 (1): 16-23.PubMed
59.
Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978, 21 (3): 274-281.CrossRefPubMed
60.
Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A: Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer. Clin Cancer Res. 2011, 17 (12): 4006-4018.CrossRefPubMed
61.
Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, Shulkes A, Baldwin GS, Patel O: The role of hypoxia-inducible factor 1alpha in determining the properties of castrate-resistant prostate cancers. PLoS One. 2013, 8 (1): e54251-PubMedCentralCrossRefPubMed
62.
Hoosein NM, Boyd DD, Hollas WJ, Mazar A, Henkin J, Chung LW: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun. 1991, 3 (8): 255-264.PubMed
63.
Tremblay L, Hauck W, Aprikian AG, Begin LR, Chapdelaine A, Chevalier S: Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer. 1996, 68 (2): 164-171.CrossRefPubMed
64.
Tremblay L, Hauck W, Nguyen LT, Allard P, Landry F, Chapdelaine A, Chevalier S: Regulation and activation of focal adhesion kinase and paxillin during the adhesion, proliferation, and differentiation of prostatic epithelial cells in vitro and in vivo. Mol Endocrinol. 1996, 10 (8): 1010-1020.PubMed
65.
Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ: Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate. 1991, 18 (3): 201-214.CrossRefPubMed
66.
Erb HH, Langlechner RV, Moser PL, Handle F, Casneuf T, Verstraeten K, Schlick B, Schafer G, Hall B, Sasser K, Culig Z, Santer FR: IL6 sensitizes prostate cancer to the antiproliferative effect of IFNalpha2 through IRF9. Endocr Relat Cancer. 2013, 20 (5): 677-689.PubMedCentralCrossRefPubMed
67.
Dunn GP, Sheehan KC, Old LJ, Schreiber RD: IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005, 65 (8): 3447-3453.PubMed
68.
Rossi MR, Hawthorn L, Platt J, Burkhardt T, Cowell JK, Ionov Y: Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet Cytogenet. 2005, 161 (2): 97-103.CrossRefPubMed
69.
Regis G, Pensa S, Boselli D, Novelli F, Poli V: Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Semin Cell Dev Biol. 2008, 19 (4): 351-359.CrossRefPubMed
70.
Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA: STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev. 2011, 22 (4): 211-219.CrossRefPubMed
71.
Qing Y, Stark GR: Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem. 2004, 279 (40): 41679-41685.CrossRefPubMed
72.
Schiavone D, Avalle L, Dewilde S, Poli V: The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3. FEBS Lett. 2011, 585 (15): 2455-2460.CrossRefPubMed
73.
74.
Stancato LF, David M, Carter-Su C, Larner AC, Pratt WB: Preassociation of STAT1 with STAT2 and STAT3 in separate signalling complexes prior to cytokine stimulation. J Biol Chem. 1996, 271 (8): 4134-4137.CrossRefPubMed
75.
76.
Epling-Burnette PK, Zhong B, Bai F, Jiang K, Bailey RD, Garcia R, Jove R, Djeu JY, Loughran TP, Wei S: Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol. 2001, 166 (12): 7486-7495.CrossRefPubMed
77.
Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, Djeu JY: Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther. 2007, 6 (11): 2938-2947.CrossRefPubMed
78.
Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ: Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A. 2002, 99 (5): 2830-2835.PubMedCentralCrossRefPubMed
79.
Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, de Kernion JB, Belldegrun AS: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer. 1996, 77 (9): 1862-1872.CrossRefPubMed
80.
Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA: BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Mol Cell Biol. 2013, 33 (4): 845-857.PubMedCentralCrossRefPubMed
81.
Feijs KL, Forst AH, Verheugd P, Luscher B: Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation. Nat Rev Mol Cell Biol. 2013, 14 (7): 443-451.CrossRefPubMed
82.
Das S, Roth CP, Wasson LM, Vishwanatha JK: Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate. 2007, 67 (14): 1550-1564.CrossRefPubMed
83.
Andersson CD, Karlberg T, Ekblad T, Lindgren AE, Thorsell AG, Spjut S, Uciechowska U, Niemiec MS, Wittung-Stafshede P, Weigelt J, Elofsson M, Schuler H, Linusson A: Discovery of ligands for ADP-ribosyltransferases via docking-based virtual screening. J Med Chem. 2012, 55 (17): 7706-7718.CrossRefPubMed
84.
Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG, Pol E, Frostell A, Ekblad T, Oncu D, Kull B, Robertson GM, Pellicciari R, Schuler H, Weigelt J: Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol. 2012, 30 (3): 283-288.CrossRefPubMed
85.
Ekblad T, Camaioni E, Schuler H, Macchiarulo A: PARP inhibitors: polypharmacology versus selective inhibition. FEBS J. 2013, 280 (15): 3563-3575.CrossRefPubMed
86.
Karlberg T, Hammarstrom M, Schutz P, Svensson L, Schuler H: Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry. 2010, 49 (6): 1056-1058.CrossRefPubMed
87.
Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Bechet JM, Dusanter-Fourt I, Bornkamm GW, Raphael M, Fagard R: Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. Blood. 2004, 104 (8): 2475-2483.CrossRefPubMed
88.
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Muller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT: TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013, 3 (5): 564-577.PubMedCentralCrossRefPubMed
89.
Yang H, Lee SM, Gao B, Zhang J, Fang D: The histone deacetylase Sirtuin 1 deacetylates IRF1 and programs dendritic cells to control Th17 differentiation during autoimmune inflammation. J Biol Chem. 2013, 288 (52): 37256-37266.PubMedCentralCrossRefPubMed
90.
Sharf R, Meraro D, Azriel A, Thornton AM, Ozato K, Petricoin EF, Larner AC, Schaper F, Hauser H, Levi BZ: Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem. 1997, 272 (15): 9785-9792.CrossRefPubMed
91.
Lin R, Hiscott J: A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol Cell Biochem. 1999, 191 (1–2): 169-180.CrossRefPubMed
92.
Shimizu T, Miyakawa Y, Oda A, Kizaki M, Ikeda Y: STI571-resistant KT-1 cells are sensitive to interferon-alpha accompanied by the loss of T-cell protein tyrosine phosphatase and prolonged phosphorylation of Stat1. Exp Hematol. 2003, 31 (7): 601-608.CrossRefPubMed
93.
ten Hoeve J, de Jesus I-SM, Fu Y, Zhu W, Tremblay M, David M, Shuai K: Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol. 2002, 22 (16): 5662-5668.PubMedCentralCrossRefPubMed
94.
Heinonen KM, Bourdeau A, Doody KM, Tremblay ML: Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-gamma signaling. Proc Natl Acad Sci U S A. 2009, 106 (23): 9368-9372.PubMedCentralCrossRefPubMed
95.
Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA: BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood. 2000, 96 (13): 4328-4334.PubMed
96.
Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, Luscher B: Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell. 2008, 32 (1): 57-69.CrossRefPubMed
97.
Hassa PO, Haenni SS, Buerki C, Meier NI, Lane WS, Owen H, Gersbach M, Imhof R, Hottiger MO: Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription. J Biol Chem. 2005, 280 (49): 40450-40464.CrossRefPubMed
98.
Sen S, Roy K, Mukherjee S, Mukhopadhyay R, Roy S: Restoration of IFNgammaR subunit assembly, IFNgamma signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterol. PLoS Pathog. 2011, 7 (9): e1002229-PubMedCentralCrossRefPubMed
99.
Yanagawa T, Funasaka T, Tsutsumi S, Hu H, Watanabe H, Raz A: Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14. Cancer Res. 2007, 67 (18): 8682-8689.CrossRefPubMed
Metadata
Title
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells
Authors
Samia B Bachmann
Sandra C Frommel
Rosalba Camicia
Hans C Winkler
Raffaella Santoro
Paul O Hassa
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-125

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-α-induced apoptosis

Research

Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription

Research

SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin

Research

Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling

Research

Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia

Erratum

Erratum to: Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits